Factor XIa inhibitors are being tested in clinical trials, with the assumption that these agents are as effective as direct oral anticoagulants but cause fewer bleeding events. Findings from phase II trials of direct inhibitors of factor XIa for the prevention of first-ever and recurrent ischaemic stroke or recurrent major coronary artery events suggest fewer bleeding events but with uncertainty about efficacy.

中文翻译：

---

凝血因子 XI 抑制剂用于心血管疾病和高出血风险患者：一个警示故事

XIa 因子抑制剂正在临床试验中进行测试，假设这些药物与直接口服抗凝剂一样有效，但出血事件较少。使用 XIa 因子直接抑制剂预防首次和复发性缺血性中风或复发性主要冠状动脉事件的 II 期试验结果表明，出血事件较少，但疗效不确定。